NASDAQ:CRDL Cardiol Therapeutics - CRDL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.66 -0.04 (-5.68%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.66▼$0.7150-Day Range$0.49▼$0.8152-Week Range$0.47▼$2.08Volume58,820 shsAverage Volume83,626 shsMarket Capitalization$42.55 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Cardiol Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside502.0% Upside$4.00 Price TargetShort InterestHealthy0.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.45) to ($0.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.28 out of 5 starsMedical Sector985th out of 1,027 stocksBiological Products, Except Diagnostic Industry165th out of 169 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Cardiol Therapeutics has a forecasted upside of 502.0% from its current price of $0.66.Amount of Analyst CoverageCardiol Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.45% of the float of Cardiol Therapeutics has been sold short.Short Interest Ratio / Days to CoverCardiol Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cardiol Therapeutics has recently increased by 6.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCardiol Therapeutics does not currently pay a dividend.Dividend GrowthCardiol Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRDL. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 3 people have searched for CRDL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cardiol Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cardiol Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.25% of the stock of Cardiol Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 7.46% of the stock of Cardiol Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cardiol Therapeutics are expected to grow in the coming year, from ($0.45) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cardiol Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cardiol Therapeutics is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCardiol Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cardiol Therapeutics (NASDAQ:CRDL) StockCardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ""ARCHER"" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.Read More Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Stock News HeadlinesJanuary 17, 2023 | finance.yahoo.comCardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for PericarditisJanuary 17, 2023 | proactiveinvestors.comCardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditisFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 14, 2022 | proactiveinvestors.comCardiol Therapeutics commences Phase II study of CardiolRx for treatment of Recurrent PericarditisDecember 12, 2022 | proactiveinvestors.comCardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditisNovember 7, 2022 | proactiveinvestors.comCardiol Therapeutics unveils new study data highlighting protective effects of CardiolRx in acute pericarditisOctober 25, 2022 | seekingalpha.comCardiol to abandon COVID study of cannabis drug to focus on heart diseases trialsAugust 3, 2022 | finance.yahoo.comCardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute MyocarditisFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...July 12, 2022 | finance.yahoo.comCardiol Therapeutics Inc. (TSE:CRDL): Are Analysts Optimistic?June 9, 2022 | finance.yahoo.comCardiol Therapeutics Announces At-The-Market Equity Offering ProgramJune 1, 2022 | benzinga.comCardiol Therapeutics (NASDAQ:CRDL), Earnings Estimates, EPS, and RevenueMay 19, 2022 | proactiveinvestors.com.auCardiol Therapeutics appoints Teri Loxam and CFO Chris Waddick to its board of directorsMay 17, 2022 | proactiveinvestors.com.auCardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditisMay 17, 2022 | proactiveinvestors.comCardiol Therapeutics gets FDA go ahead for Investigational New Drug Application for CardiolRxMay 17, 2022 | finance.yahoo.comCardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent PericarditisMay 2, 2022 | finance.yahoo.comWe're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash BurnMarch 15, 2022 | proactiveinvestors.comCardiol Therapeutics says Jennifer M. Chao has been appointed as director of the companyMarch 15, 2022 | finance.yahoo.comCardiol Therapeutics Appoints Jennifer M. Chao to Its Board of DirectorsJanuary 20, 2022 | seekingalpha.comNeuroMetrix, Mainz lead healthcare gainers; Dyne, Allarity among losersJanuary 6, 2022 | nasdaq.comCardiol Therapeutics Inc - Class A Shares Near 52-Week Low - Market MoverNovember 5, 2021 | proactiveinvestors.comCardiol Therapeutics raises US$50M to advance research and clinical development initiativesNovember 5, 2021 | proactiveinvestors.comCardiol Therapeutics completes massive financing adding 50 million US to the treasuryNovember 5, 2021 | finance.yahoo.comCardiol Therapeutics Announces Closing of US$50 Million Public OfferingOctober 25, 2021 | finance.yahoo.comCardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute MyocarditisSeptember 16, 2021 | finance.yahoo.comCardiol Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare ConferenceAugust 26, 2021 | ca.finance.yahoo.comStocks in play: Cardiol Therapeutics Inc.See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Company Calendar Last Earnings11/10/2022Today2/06/2023Next Earnings (Estimated)3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRDL CUSIPN/A CIK1702123 Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+502.0%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($0.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-44.32% Return on Assets-38.18% Debt Debt-to-Equity RatioN/A Current Ratio7.02 Quick Ratio7.02 Sales & Book Value Annual Sales$60,000.00 Price / Sales709.14 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book0.68Miscellaneous Outstanding Shares64,040,000Free Float60,681,000Market Cap$42.55 million OptionableNot Optionable Beta-0.19 Key ExecutivesDavid G. ElsleyPresident, Chief Executive Officer & DirectorBernard LimChief Operating OfficerChristopher J. WaddickChief Financial Officer, Secretary & DirectorAndrew HamerChief Medical Officer, Head-Research & DevelopmentBlagoja RistevskiDirector-Chemical Engineering & ManufacturingKey CompetitorsTScan TherapeuticsNASDAQ:TCRXERYTECH PharmaNASDAQ:ERYPAVROBIONASDAQ:AVROAchilles TherapeuticsNASDAQ:ACHLOKYO PharmaNASDAQ:OKYOView All CompetitorsInsiders & InstitutionsBank of Montreal CanBought 75,269 shares on 2/1/2023Ownership: 0.141%Two Sigma Advisers LPSold 26,600 shares on 11/15/2022Ownership: 0.056%View All Institutional Transactions CRDL Stock - Frequently Asked Questions What is Cardiol Therapeutics' stock price forecast for 2023? 0 Wall Street research analysts have issued 1 year price objectives for Cardiol Therapeutics' shares. Their CRDL share price forecasts range from $1.00 to $7.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 502.0% from the stock's current price. View analysts price targets for CRDL or view top-rated stocks among Wall Street analysts. How have CRDL shares performed in 2023? Cardiol Therapeutics' stock was trading at $0.51 at the beginning of 2023. Since then, CRDL shares have increased by 30.3% and is now trading at $0.6644. View the best growth stocks for 2023 here. When is Cardiol Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our CRDL earnings forecast. How were Cardiol Therapeutics' earnings last quarter? Cardiol Therapeutics Inc. (NASDAQ:CRDL) released its quarterly earnings results on Thursday, November, 10th. The company reported ($0.10) earnings per share for the quarter. What is Cardiol Therapeutics' stock symbol? Cardiol Therapeutics trades on the NASDAQ under the ticker symbol "CRDL." Who are Cardiol Therapeutics' major shareholders? Cardiol Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.14%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Cardiol Therapeutics? Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cardiol Therapeutics' stock price today? One share of CRDL stock can currently be purchased for approximately $0.66. How much money does Cardiol Therapeutics make? Cardiol Therapeutics (NASDAQ:CRDL) has a market capitalization of $42.55 million and generates $60,000.00 in revenue each year. The company earns $-25,240,000.00 in net income (profit) each year or ($0.38) on an earnings per share basis. How can I contact Cardiol Therapeutics? The official website for the company is www.cardiolrx.com. The company can be reached via phone at (289) 910-0850 or via email at trevor.burns@cardiolrx.com. This page (NASDAQ:CRDL) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.